Clinical trial · Observational
A Study on the Efficacy and Safety of IPyC for HER2+ MBC
A Retrospective Multicenter Cohort Study on the Efficacy and Safety of Inetetamab and Pyrotinib Combined With Chemotherapy for HER2-positive Metastatic Breast Cancer
NCT06990347CI-TRIAL-00090143completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Between July 2020 and August 2024, 301 HER2-positive MBC patients from five tertiary centers received the regimen until disease progression or unacceptable toxicity. Efficacy endpoints included progression-free survival (PFS), objective response rate (ORR), and clinical benefit rate (CBR).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Inetetamab and Pyrotinib Combined with Chemotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- progression-free survival (PFS)
- timeFrame
- 2 years
Secondary outcomes (2)
- measure
- objective response rate (ORR)
- timeFrame
- 2 years
- measure
- clinical benefit rate (CBR)
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * patients who underwent a biopsy of the metastatic site and were confirmed as having MBC * patients who received inetetamab + pyrotinib + chemotherapy as metastasis therapy. Exclusion Criteria: * male patients or individuals with prior malignancy * patients with prior or current enrollment in interventional clinical trials for MBC * patients who received less than 2 cycles of treatment (6 weeks of inetetamab or 8 weeks of pyrotinib) * patients who were lost to follow-up during the therapeutic process
References
Publications (0)
Data not yet available
No reference posted for this study.